Showing results (1-10 of 64) with videos related to
Sort By:
Pageof 7
Diabetes/Metabolism Research and Reviews|July 24, 2023
Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?Mark M Smits, Jens J HolstFrontiers in Endocrinology|December 3, 2021
Corrigendum: Safety of SemaglutideMark M Smits, Daniël H Van RaalteThe New Phytologist|August 22, 2006
Ectomycorrhizal weathering of the soil minerals muscovite and hornblendeLaura van Schöll, Mark M Smits, Ellis HofflandNature Reviews. Gastroenterology & Hepatology|February 10, 2011
The clinical significance of pancreatic steatosisMark M Smits, Erwin J M van GeenenCurrent Atherosclerosis Reports|January 10, 2013
Advances in pharmacologic therapies for type 2 diabetesLinde M Morsink, Mark M Smits, Michaela DiamantCurrent Opinion in Lipidology|July 31, 2024
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?Teba Alnima, Mark M Smits, Nordin M J HanssenCardiovascular Research|December 12, 2019
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomesValerie D Heuvelman, Daniël H Van Raalte, Mark M SmitsThe New Phytologist|March 22, 2016
The role of phosphorus, magnesium and potassium availability in soil fungal exploration of mineral nutrient sources in Norway spruce forestsNicholas P Rosenstock, Christoffer Berner, Mark M Smits, et al.Nature Reviews. Nephrology|December 31, 2013
The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Marcel H A Muskiet, Mark M Smits, Linde M Morsink, et al.Pageof 7